Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT04564274

NCT04564274
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • The person being reported on must be at least 1 month old
  • The person filling out the report must have access to the internet and be able to read and answer questions in English or Spanish

Who may not be able to join:

  • People who are not willing to allow their research data to be shared with other researchers cannot participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registry
clinicaltrials_gov
Start date
4 October 2020
Est. completion
20 May 2022

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov